Business UpdateJun 8, 2026, 07:01 AM
Tonix Pharma TONMYA Coverage Expands to 52M Lives (29% US Commercial)
AI Summary
Tonix Pharmaceuticals announced an agreement with a second leading group purchasing organization (GPO), effective June 1, 2026, expanding commercial coverage for TONMYA to an additional 17 million U.S. lives. This new agreement brings the total commercial coverage for TONMYA to approximately 52 million lives, representing about 29% of the total U.S. commercial lives. TONMYA, the first new FDA-approved fibromyalgia medicine in over 15 years, is also available in most states under Medicaid, covering approximately 75 million lives.
Key Highlights
- Tonix secured a second GPO agreement for TONMYA, effective June 1, 2026.
- This agreement adds approximately 17 million U.S. commercial lives to TONMYA's coverage.
- Total commercial coverage for TONMYA now reaches approximately 52 million U.S. lives.
- This represents about 29% of the total U.S. commercial lives.
- TONMYA is also available under Medicaid for approximately 75 million lives.
- TONMYA is the first new FDA-approved fibromyalgia medicine in over 15 years.
- Patents for TONMYA are expected to provide U.S. market exclusivity until 2034.
Price Impact
More from TNXP